Figure 4

Selective inhibition of BDNF and prodynorphin signaling during morphine treatment attenuates opioid induced hyperalgesia. ANA-12 (TrkB receptor antagonist, 0.5 mg/kg) or nor-BNI (KOR antagonist, 0.5 mg/kg) administration once daily with morphine during the 4 days of escalating morphine treatment resulted in attenuation of sensitization on day 5 (A-B). However, only ANA-12 was associated with less sensitization in the morphine + SAHA group on day 12 (one week after completion of drug administration). Error bars: SEM, n = 6/group, ns: p > 0.05, *p < 0.05, **p < 0.01 and ***p < 0.001 for comparison between treatments for each timepoint. Data for each timepoint were analyzed by one-way ANOVA followed by Sidak multiple comparisons tests.